BMS woes continue, page-2

What woes?
these BMS and Merck checkpoint inhibitor drugs already have a long list of approved indications in multiple cancer types .
then their pipelines, a ton of trials already in progress testing multiple different combinations.
so yes they’re looking for ways to increase effectiveness of their drugs, but doesn’t mean NOX is the answer.

looking at company announcements there appears to be lot of hype but actually modest data obtained so far , but one could be forgiven for thinking there’s something special and unique about the Nox drug in this checkpoint inhibitor combination space, but really there isn’t if you looked at what else is out there . I just don’t see that in the boardrooms of New York or New Jersey all eyes of BMS or Merck senior executives are trained on Ionic.